Drucker Wealth 3.0 LLC Sells 30,539 Shares of Pfizer Inc. $PFE

Drucker Wealth 3.0 LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 51.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 29,078 shares of the biopharmaceutical company’s stock after selling 30,539 shares during the quarter. Drucker Wealth 3.0 LLC’s holdings in Pfizer were worth $817,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Simmons Bank grew its stake in Pfizer by 1.0% in the first quarter. Simmons Bank now owns 149,603 shares of the biopharmaceutical company’s stock valued at $4,201,000 after purchasing an additional 1,517 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ boosted its holdings in shares of Pfizer by 3.4% in the 1st quarter. Lansforsakringar Fondforvaltning AB publ now owns 3,158,825 shares of the biopharmaceutical company’s stock valued at $88,699,000 after buying an additional 103,600 shares during the last quarter. Next Level Private LLC boosted its holdings in shares of Pfizer by 40.1% in the 1st quarter. Next Level Private LLC now owns 87,167 shares of the biopharmaceutical company’s stock valued at $2,448,000 after buying an additional 24,966 shares during the last quarter. North Star Investment Management Corp. increased its holdings in Pfizer by 12.2% during the first quarter. North Star Investment Management Corp. now owns 181,035 shares of the biopharmaceutical company’s stock worth $5,083,000 after buying an additional 19,625 shares during the last quarter. Finally, 3Chopt Investment Partners LLC lifted its stake in Pfizer by 19.5% in the first quarter. 3Chopt Investment Partners LLC now owns 10,467 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 1,706 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Guggenheim upped their target price on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. UBS Group reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research note on Monday, March 2nd. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent’s GLP-1 drugs reportedly cleared a preliminary China insurance review, which could improve the commercial outlook for Ecnoglutide if it is eventually added to the country’s basic medical insurance catalogue. Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and dividend stock, with bullish arguments pointing to its lower forward valuation and income appeal, which may be helping sentiment around the shares. Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
• Positive Sentiment: Pfizer is also being highlighted as one of several reliable dividend names in a volatile market, reinforcing the stock’s defensive-income profile for investors. 3 No-Brainer Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer signed a SuperHuman platform license agreement with Distributed Bio, which is a strategic R&D move but not yet a clear near-term earnings driver. Wired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed Bio
• Negative Sentiment: Recent coverage also continues to weigh on sentiment, noting a CFO departure and a late-stage clinical miss in Pfizer’s oncology pipeline, which reinforces concerns about execution and growth prospects. Read More.

Pfizer Trading Up 0.4%

Shares of Pfizer stock opened at $24.39 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a 50-day moving average of $25.88 and a 200-day moving average of $26.28. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The stock has a market cap of $139.04 billion, a PE ratio of 18.62 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.